Acrux completes Phase I trial of testosterone lotion
Wednesday, 06 October, 2004
Acrux (ASX: ACR) has completed a Phase I clinical trial of its testosterone metered-dose lotion for the treatment of hypogonadism, or low testosterone, in men.
The proof-of-concept study compared Acrux's product with the current market leader, a commercially available testosterone gel in five men with low testosterone. The trial was performed at Prince Henry's Institute of Medical Research in Melbourne, and was sponsored by Acrux subsidiary Acrux DDS.
The company will now seek advice on the appropriate regulatory path for approval in major world markets including the US, CEO Igor Gonda said.
Global study finds 250 genes linked to OCD
Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...
TGA approves therapy for paediatric growth hormone deficiency
The TGA has approved SKYTROFA as a treatment for growth failure in children and adolescents aged...
Immune cell boost could enable lasting vaccine protection
A research team has found a promising new way to enhance the effectiveness of vaccines by tapping...
